AMW GmbH
Booth number: 4315-15
a-m-w.eu
About us
AMW is a specialty bio-pharmaceutical company focused on biodegradable sustained-release drug delivery systems, providing patients and partners access to value-added medicines and cost-effective therapies. Based on its technology platform, the Company builds on a growing own and partnered development pipeline. AMW has two approved products, goserelin and leuprorelin implants, which are distributed worldwide through both local and global pharma partners. In Germany, leuprorelin is marketed as Leugon® by AMW’s wholly owned subsidiary Endomedica GmbH. To support pharma and biotech partners in the development and manufacturing of their products and life-cycle solutions, AMW uses its leading-edge formulation development expertise.AMW is based in Warngau near Munich, Germany.
Address
Birkerfeld 11
83627 Warngau
Germany
Phone: +49 8024 470999-0
Contact person:
Dr. Joao Silva
Senior Business Development Manager
E-mail: j.silva@a-m-w.eu
Phone: +49 151 72365411
Dr. Andrey Molchanov
Vice President Business Development/RA
E-mail: a.molchanov@a-m-w.eu
Phone: +49 160 7851948
Products & Services
AMW is a German-based innovative specialty bio-pharmaceuticals company focused on developing and manufacturing high-quality advanced drug delivery systems for a broad range of indications. Our current focus is on subcutaneous biodegradable slow-release implants, utilizing our drug delivery technology platform and deep galenic and formulation expertise for the development and manufacture of novel compounds and complex generics/ value-added medicines.
Two products from AMW’s pipeline are currently sold on international markets:
Goserelin Implant – prostate/breast cancer;
Leuprorelin Implant - prostate cancer;
AMW is buiding a pipeline of both proprietary and partnered products in different therapeutic areas such as oncology, ophthalmology, obesity, CVD and diabetes.
The Company has established partnerships with worldwide renowned international pharmaceutical companies and is interested in further out-licensing and development partnerships.
